Pick of the Week: Biocon

14th January 2019

Biocon, Asia¡¦s largest biotechnology company, started itself with seed capital of Rs.10,000 in 1978, is now a billion dollar company. The company manufactures biotechnological products catering to the healthcare segment. It engages itself in all phases of the product cycle from discovering to development & then commercializing the same drugs. This pharmaceutical company has fermentation-based technology, creating cost effective drugs. Syngene and Clinigene, subsidiaries of Biocon conduct R&D programs for international pharmaceutical and biotechnology majors.
Biocon produces anti diabetic agents like Acarbose, Pioglitazone, Repaglinides & Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase & Monoclonal Antibodies. The drug major produces mycophenolate mofetil, sirolimus and tacrolimus. It also produces & market mix of specialty & industrial enzymes for industries like paper, brewing, beverages, food, brewing, textiles & distilling. The company¡¦s drug portfolio consists of lovastatin, simvastatin, pravastatin and atorvastatin.


Biocon¡¦s fully integrated business model spans the entire drug value chain, from pre-clinical discovery to clinical development and through to commercialisation. Its businesses in custom research (Syngene), clinical development (Clinigene) and biopharmaceuticals (Biocon) provide multiple revenue streams to balance risk, drive innovation, deliver products and accelerate growth. As the company increases the complexity and scope of its own R&D and manufacturing operations, especially in new product discovery and development, it believes that the custom and clinical research services will continue to offer important synergies.

Company Name

BIOCON LIMITED.

Our Recommentation is to

Buy

Buy

645.45

Targeted Price

720

Stop Loss

607

Trending Reports

Sachin Gupta’s View: COPPER|31DEC20 (MCX)

Technical

26th November 2020

A V Sathish's View: MCXBULLDEX|24DEC20 (MCX)

Technical

26th November 2020

*Only for those online clients who are opening accounts without any referral code

Quick Links